Related Experiment Video
Updated: May 8, 2026
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
Estrogen-induced cholestasis: pathogenesis and therapeuticimplications
Hepato-Gastroenterology
|August 13, 2013
Summary
Estrogen impairs bile acid transport in liver cells, causing cholestasis. Combined therapies targeting estrogen and bile acid circulation may offer effective treatment for this common liver condition.
Area of Science:
- Hepatology and Molecular Medicine
- Endocrinology and Metabolism
Background:
- Cholestasis syndromes, characterized by impaired bile formation and secretion, arise from diverse etiologies.
- Estrogen-induced cholestasis is a prevalent clinical manifestation within these syndromes.
- Understanding the molecular mechanisms of bile acid transport is crucial for deciphering cholestasis pathogenesis.
Purpose of the Study:
- To elucidate the molecular mechanisms by which estrogen induces cholestasis.
- To identify potential therapeutic strategies for estrogen-induced cholestasis.
Main Methods:
- Investigated the effects of estrogen on key bile acid transporters in hepatocytes.
- Analyzed the impact of estrogen on bile acid uptake and efflux pathways.
- Explored the role of estrogen receptors in mediating cholestatic effects.
Main Results:
- Estrogen inhibits bile acid transport from hepatocytes into bile canaliculi by affecting the bile salt export pump (BSEP) and multidrug resistance-associated transporter 2 (MRP2).
- Estrogen interferes with the uptake of bile acids by inhibiting the Na+-taurocholate cotransporting polypeptide (NTCP) and Na+-independent organic anion-transporting polypeptides (OATPs) on the basolateral membrane.
- These molecular disruptions lead to impaired bile acid homeostasis and cholestasis.
Conclusions:
- Estrogen exerts its cholestatic effects through direct inhibition of critical bile acid transporters involved in both efflux and uptake.
- A co-treatment strategy combining nuclear receptor inducers and cAMP enhancers to boost transporter activity, alongside agents reducing estrogen levels and enterohepatic circulation of bile acids, shows therapeutic promise.
Related Concept Videos
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...